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Introduction
The dominant cellular basis of obesity is increased fat cell size 
during  the  adipocyte  differentiation  process.  The  process  is 
marked by accretion of triglycerides within intracellular lipid 
droplets (Farmer, 2006). Adipogenesis is tightly regulated by 
peroxisome proliferator activated receptor  (PPAR), a mem-
ber of the ligand-activated nuclear receptor superfamily of 
transcription factors. Mechanistically, exogenous (thiazolidine-
diones) or endogenous (eicosanoids) ligands activate PPAR by 
stabilizing the active conformation of the ligand-binding domain 
(Nolte et al., 1998) to induce or repress a wide array of differ-
entiation-dependent and adipose-specific genes. PPAR mRNA 
and protein expression are robustly induced in a feed-forward 
loop with CAAT/enhancer binding protein- (C/EBP) during 
adipogenesis (Wu et al., 1999; Rosen et al., 2002). The process 
is initially stimulated by several up-stream transcription factors: 
C/EBP, C/EBP (Yeh et al., 1995; Wu et al., 1996; Zuo et al., 
2006), and coregulators, including the p160 class of steroid re-
ceptor coactivators (SRCs; Louet and O’Malley, 2007).
A critical step required for adipogenesis is the down- 
regulation of kinase signaling pathways targeting PPAR to   
permit its full transcriptional activity (Hu et al., 1996; Adams 
et al., 1997; Camp and Tafuri, 1997). Specifically, the pro- 
adipogenic function of PPAR is decreased by mitogen-activated 
protein kinase (MAPK) phosphorylation in the N-terminal A/B   
region  (mouse  S112/human  S114),  which  concomitantly  re-
duces thiazolidinedione affinity for PPAR (Shao et al., 1998). 
Overexpression of a nonphosphorylatable form of PPAR pro-
motes insulin sensitization and elevated adipogenesis in 3T3L1 
(Hu et al., 1996; Shao et al., 1998). Additionally, mouse em-
bryonic fibroblasts expressing a serine-to-alanine substitution at   
codon 112 (Rangwala et al., 2003) exhibit a similar effect. PPAR 
phosphorylation  at  S112/S114  also  decreases  interactions  with 
T
he related coactivators SRC-2 and SRC-3 interact 
with  peroxisome  proliferator  activated  receptor   
(PPAR) to coordinate transcriptional circuits to pro-
mote adipogenesis. To identify potential coactivator re-
dundancy  during  human  adipogenesis  at  single  cell 
resolution, we used high content analysis to quantify   
links  between  PPAR,  SRC-2,  SRC-3,  and  lipogenesis.   
Because  we  detected  robust  increases  and  significant   
cell–cell heterogeneity in PPAR and lipogenesis, with-
out changes in SRC-2 or SRC-3, we hypothesized that 
permissive coregulator levels comprise a necessary adi-
pogenic  equilibrium.  We  probed  this  equilibrium  by 
down-regulating  SRC-2  and  SRC-3  while  simultaneously 
quantifying  PPAR.  Individual  or  joint  knockdown   
equally inhibits lipid accumulation by preventing lipo-
genic gene engagement, without affecting PPAR protein 
levels.  Supporting  dominant,  pro-adipogenic  roles  for 
SRC-2 and SRC-3, SRC-1 knockdown does not affect   
adipogenesis. SRC-2 and SRC-3 knockdown increases 
the  proportion  of  cells  in  a  PPAR
hi/lipid
lo  state   
while  increasing  phospho-PPAR–S114,  an  inhibitor   
of  PPAR  transcriptional  activity  and  adipogenesis.   
Together,  we  demonstrate  that  SRC-2  and  SRC-3  con-
comitantly promote human adipocyte differentiation by 
attenuating phospho-PPAR–S114 and modulating PPAR 
cellular heterogeneity.
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to SRC-3
/ mice, which provides evidence of a dominant pro-
adipogenic role for SRC-3.
Although  the  similarities  observed  among  SRC-2  and 
SRC-3 knockout mice indicate a functional overlap and domi-
nant pro-adipogenic roles, no data exists on the contributions of   
cell–cell variability between SRC-2, SRC-3, and PPAR that   
collectively and/or redundantly promote human adipogenesis. 
Accordingly, the purpose of this study was to focus upon SRC-2 
and SRC-3 and dissect the early interplay between these co-
activators and PPAR that converts a human preadipocyte into a 
mature fat cell. Here, we developed and used a high-throughput 
microscopy-based,  high-content  analysis  (HCA)  approach  to 
quantify the effects of SRC loss of function on the cell-to-cell 
population  dynamics  of  PPAR.  Our  results  emphasize  the 
novel regulatory role of steady-state levels of SRC-2 and SRC-3 
in human adipogenesis, specifically by promoting lipid accu-
mulation under both high and low PPAR phenotypes marked 
by attenuation of PPAR phosphorylation at S114.
Results
Human adipocyte differentiation occurs 
independently of static SRC mRNA profiles
SRCs have been shown to be critical elements of the murine 
adipogenic gene program (Picard et al., 2002; Louet et al., 2006; 
SRCs (Shao et al., 1998), resulting in a potential negative   
cooperative effect on PPAR-regulated, adipocentric genes.
The p160 family of SRCs (SRC-1, SRC-2, and SRC-3) de-
fined the first class of coregulators (CoR) that enhance nuclear 
receptor transactivation in a ligand-dependent manner, bridging 
NRs to other components of the basal transcriptional machinery 
and integrating both genomic and nongenomic signals (Oñate 
et al., 1995; Anzick et al., 1997; Hong et al., 1997). Depending 
on the ligand context, biochemical assays have shown that each 
of the SRCs potentiate the transcriptional activity of PPAR 
through  direct  interactions  (McInerney  et  al.,  1998;  Kodera 
et al., 2000; Rocchi et al., 2001; Louet et al., 2006). However, 
SRC-2 and SRC-3 share the highest degree of sequence ho-
mology and promote adipogenesis in knockout mouse models. 
SRC-2
/ mice are protected from obesity because of enhanced 
energy expenditure, decreased white adipocyte differentiation, 
and increased thermogenic activity of brown adipose (Picard 
et al., 2002). SRC-3 ablation leads to lean mice with increased 
energy expenditure and decreased adipogenesis (Louet et al., 
2006; Coste et al., 2008). However, upon high-fat diet feed-
ing, SRC-1
/ knockout mice are slightly prone to obesity be-
cause of both a reduced capacity for fatty acid oxidation and 
decreased energy expenditure (Picard et al., 2002). Moreover, 
double knockout of SRC-1 and SRC-3 results in a lean pheno-
type and increased metabolic rate (Wang et al., 2006), similar 
Figure 1.  Expression of SRC-2, SRC-3, PPAR, and adipocentric genes during human adipocyte differentiation. Subcutaneous human preadipocytes were 
differentiated for 4 d, and total mRNA was isolated at each indicated interval. The mRNA levels of SRC-1, SRC-2, and SRC-3 (A); and PPAR2, C/EBP, 
SREBP1c, ADFP, and FASN (B) were determined by qPCR. -actin served as an internal control. RNA was collected from at least two independent isolations 
and error bars represent SEM. Asterisks indicate levels of induction statistically different from 0 h (P < 0.05).57 p160 coactivators promote adipocyte heterogeneity • Hartig et al.
After 7 d, 88.1% of cells were positive for lipids, which sug-
gests that the preadipocyte cell population responds robustly 
to chemical induction of adipogenesis in a unidirectional man-
ner (Fig. S1 A). Consistent with the qPCR results (Fig. 1 A), 
SRC-1  was  significantly  increased  (50%),  whereas  modest, 
statistically insignificant changes in SRC-2 (15%) and SRC-3 
(22%) were detected. Using additional software with built-in   
lipid droplet analysis tools (McDonough et al., 2009), we 
detected  increases  in  the  number  of  lipid  droplets/nuclei 
(+250%; Fig. 2 D), total lipid droplet area (+120%; Fig. 2 E),   
and  lipid  content/cell  (12-fold  induction;  Fig.  2  F).  Dose 
response experiments using rosiglitazone (BRL49653) or a 
natural PPAR ligand (15-deoxy-12,14-prostaglandin J2; 
15dPGJ2)  showed  that  both  ligands  increase  lipogenesis   
(Fig. S1 B), PPAR (Fig. S1 C), and SRC-1 levels (Fig. S1 D). 
Increasing concentrations of 15dPGJ2 and BRL49653 did not 
significantly alter the protein expression of SRC-2 (Fig. S1 E) 
and SRC-3 (Fig. S1 F).
Cell-to-cell measurements of lipids as a 
function of PPAR represent population 
heterogeneity during human adipogenesis
At  the  population  level,  the  time-dependent  induction  of 
PPAR was positively correlated with the accumulation of 
lipids, which is consistent with previously established deter-
ministic paradigms of PPAR-mediated adipogenesis (Rosen 
et al., 1999). However, when the differentiating fraction of 
preadipocytes was quantitatively examined at the single cell 
level, a large degree of population heterogeneity was observed, 
which is in agreement with recent studies on the 3T3L1 dif-
ferentiation program (Loo et al., 2009). These subpopulation 
changes were apparent as early as 24 h after MIX treatment, 
and more visible at 96 h (Fig. 3 A). This heterogeneity is   
illustrated in Fig. 3 B by plotting, on a cell-by-cell basis,   
Coste et al., 2008). Given these results, we used quantitative 
RT-PCR  (qPCR)  to  measure  mRNA  expression  during  the   
first 4 d of human adipocyte differentiation with rosigli-
tazone,  dexamethasone,  3-isobutyl-1-methylxanthine  (IBMX),   
and  insulin  (MIX).  Surprisingly,  we  found  that  although   
SRC-1  mRNA  levels  were  increased  twofold,  SRC-2  and 
SRC-3 were not changed during the first 4 d of differentiation   
(Fig. 1 A). We also measured mRNA levels of several tran-
scription  factors  that  stimulate  differentiation  and  markers 
of lipogenesis (Fig. 1 B). The mRNA levels of C/EBP (40-
fold), PPAR (10-fold), SREBP1c (10-fold), FASN (20-fold), 
and ADFP (threefold) were up-regulated in response to 96 h 
of treatment with MIX. These initial experiments suggested 
that human adipocytes maintain constant SRC-2 and SRC-3 
mRNA levels while up-regulating SRC-1 transcripts during 
early differentiation.
HCA of human adipocyte cell populations 
validates mRNA results for SRCs  
and PPAR
To further understand the dynamics of SRC-1, SRC-2, SRC-3, 
and PPAR during differentiation, we validated the mRNA 
profiling (Fig. 1) with protein and lipid measurements at the 
single cell level using HCA. Subcutaneous preadipocytes were 
differentiated for 4 d, then fixed and labeled for DNA (DAPI), 
SRC-1, SRC-2, SRC-3, or PPAR. Lipid droplets were labeled 
with  a  fluorescent  neutral  lipid  dye  to  mark  differentiating 
cells. We next quantified changes in these properties for each 
cell  (≥1,000  cells/condition/experiment),  by  automated  cell 
and nucleus identification (Fig. 2 A) with both in-house algo-
rithms  and  commercially  available  software.  As  indicated 
in Fig. 2 B, mean PPAR protein levels increased monotoni-
cally (2.8-fold) over the first 4 d, which correlates with an ap-
proximately eightfold induction of lipid accumulation (Fig. 2 C).   
Figure  2.  Development  of  an  image-based 
analysis  platform  to  study  PPAR  and  co-
activator  expression  in  human  adipocytes.  
(A) Shown are representative grayscale images   
of adipocytes differentiated for 96 h, immuno-
labeled  with  antibodies  to  SRC-2  or  SRC-3, 
and then stained with DAPI, CMBl, and Lipid-
TOX (Lipid). Binary nuclear and cellular masks 
were generated by a combination of watershed 
and threshold image transformations (Pipeline   
Pilot; Accelrys). Nuclear masks are indicated 
in green; whole cell masks are shown in red. 
(B–F) Nuclear and cellular masks were used to 
extract pixel-based measurements that describe 
nuclear  PPAR,  SRC-1,  SRC-2,  SRC-3  levels 
(B) and lipid accumulation (C) during a 96-h   
differentiation  period.  Additional  software 
(CyteSeer; Vala Sciences) was used to calcu-
late  the  number  of  lipid  droplets/nuclei  (D),   
lipid droplet area (E), and fold induction of 
lipid (F). Experiments shown are the mean of 
11 independent experiments. Values are the 
mean fold induction. Error bars indicate SEM 
(*, P < 0.05 compared with 0 h). Bar, 50 µm.JCB • VOLUME 192 • NUMBER 1 • 2011   58
SRC-2 and SRC-3 levels are correlated 
with PPAR-dependent lipogenesis
Biochemical studies and mouse models have indicated that pro-
adipogenic transcriptional activity of PPAR is maintained by 
functional interactions with the coactivators SRC-2 and SRC-3 
(McInerney et al., 1998; Rocchi et al., 2001; Louet et al., 2006). 
Therefore, we sought to understand the single cell relationship 
between these SRCs and PPAR. First, we analyzed the level 
of heterogeneity that existed for both SRC-2 and SRC-3 in 
individual cells during the first 96 h of human adipocyte differen-
tiation. Analysis of the cell–cell heterogeneity in both SRC-2 
(Fig. 4 A) and SRC-3 (Fig. 4 B) levels indicated a <10-fold 
lower range of expression levels compared with PPAR (>100-
fold). This tighter range of SRC-2 or SRC-3 levels was consis-
tent with (96 h) and without (0 h) differentiation, whereas lipid 
content increased independent of single cell SRC-2 and SRC-3 
expression. We further represented this contrast in variability 
by calculating the coefficient of variation (CV = /) after   
96 h of differentiation, where a higher CV indicates wider sys-
tem heterogeneity. In agreement with scatter plot representations 
of PPAR (Fig. 3 B), SRC-2 (Fig. 4 A), and SRC-3 (Fig. 4 B), 
CVs for PPAR and lipid were significantly greater than those 
calculated for SRC-2 and SRC-3.
Next, we simultaneously detected SRC/PPAR (Fig. 4 F) 
to determine if there were cells with SRC-2 or SRC-3 levels   
that  correlated  with  PPAR  and/or  lipids.  Individual  cell 
measurements of PPAR and SRC were normalized to their 
respective median intensities at 96 h. PPAR normalization 
cellular lipid content as a function of nuclear PPAR protein 
levels. At 96 h after induction by MIX, 100-fold variation 
in PPAR and a range of three orders of magnitude in lipid 
content were observed. This was an undetectable response at 
the median protein (immunofluorescence; Fig. 2) and mRNA 
levels (qPCR; Fig. 1). To explore this heterogeneity across 
experiments, we subdivided the cell populations. For each 
experiment and time point, individual cell measurements of 
PPAR and lipid were normalized to the median intensity at 
96 h, which set the threshold for quadrant subdivision for 
both properties arbitrarily equal to 1. This threshold was then 
applied to each time point. Subsequently, this created four 
subpopulation quadrants (Fig. 3 C): high PPAR/high lipid 
(PPAR
hi/lipid
hi),  high  PPAR/low  lipid  (PPAR
hi/lipid
lo), 
low PPAR/low lipid (PPAR
lo/lipid
lo), and low PPAR/high 
lipid (PPAR
lo/lipid
hi). Temporal analysis of these quadrants 
showed that the PPAR
hi/lipid
hi population increased from 2% 
after 24 h of differentiation to 33% at 96 h. More interestingly, 
however, was the up-regulation of the PPAR
hi/lipid
lo popula-
tion at 24 h (21% change) followed by a decrease (12%) at 
96 h. Based on these results, the nonessential role of SRC-1 
(Fig. S2), and the central functions of SRC-2 and SRC-3 in 
adipogenesis (Picard et al., 2002; Louet et al., 2006; Wang   
et al., 2006; Coste et al., 2008), we proposed that variation in 
PPAR (Fig. 3 C) might be dictated by factors, specifically 
SRC-2 and SRC-3, whose overall expression level was not 
regulated by differentiation but nonetheless were important 
for the early human adipogenic phenotype.
Figure 3.  Population dynamics of PPAR protein 
expression as a function of lipid content during 
the  early  phases  of  human  adipocyte  differen-
tiation. (A) Representative images of adipocytes 
during  differentiation  were  immunolabeled  for 
PPAR, and lipids were labeled and imaged by 
high throughput microscopy (HTM). Bar, 50 µm. 
(B) Cell-to-cell variation in PPAR and lipids dur-
ing the first 96 h of differentiation was monitored. 
One representative experiment is shown. Individ-
ual cell measurements of PPAR and lipid were 
normalized to the median intensity at 96 h, which 
set  a  threshold  (dotted  lines)  that  was  applied 
to  each  time  point  to  create  the  PPAR
x/lipid
y 
populations. An example cell is shown from each 
quadrant. Bar, 20 µm. (C) Pie charts are shown 
that indicate the change in population distribution 
over this time period after median threshold appli-
cation (n = 5 independent experiments).59 p160 coactivators promote adipocyte heterogeneity • Hartig et al.
and lipids exhibited a less pronounced relationship. Specifi-
cally, SRC-2 and SRC-3 intensities within cell subpopulations 
defined by PPAR and lipid levels in Fig. 3 showed that the 
PPAR
hi/lipid
hi cells had significantly higher levels of SRC-2 
or SRC-3 than the other quadrants (Fig. 4 H). Interestingly, 
this population also had significantly higher correlation co-
efficients between SRC-2/PPAR and SRC-3/PPAR. In con-
trast, PPAR
hi/lipid
lo cells exhibited the lowest SRC/PPAR 
correlation (Table I).
The correlations between SRCs and PPAR established 
a quantitative relationship between lipid, PPAR, and SRC 
levels in human adipocytes, but did not indicate the nature 
of the interaction between these proteins. To visualize the   
interactions between PPAR/SRC-2 and PPAR/SRC-3 occur-
ring in response to differentiation cues, we used sensitized 
emission fluorescence resonance energy transfer (seFRET). 
set  the  threshold  for  binary  subdivision  into  PPAR
lo  and 
PPAR
hi populations arbitrarily equal to 1. This threshold was 
then applied to each time point, and normalized SRC levels 
were calculated. As shown in Fig. 4 D, SRC-2 levels were 
higher in the PPAR
hi population across all time points. SRC-3 
(Fig. 4 E) showed a similar pattern at 24 h and 96 h only. The 
SRC-2 and SRC-3 levels in the PPAR
lo and PPAR
hi were 
not  affected  by  differentiation,  which  suggested  that  these 
populations might represent, in terms of SRC and PPAR, 
similar biological states. Single cell analysis of the correla-
tion (Pearson’s r [Pr]) between SRC and PPAR levels at 96 h 
showed significant, positive correlation between both SRC-2 
and PPAR (Pr = 0.39, n = 6) and SRC-3 and PPAR (Pr = 
0.33, n = 6). Contour mapping (Fig. 4 G) of lipid intensity, 
as a function of SRC and PPAR, showed that high SRC-2 
and PPAR correlated with increased lipids. SRC-3, PPAR, 
Figure 4.  Cell-to-cell relationships between SRC-2, SRC-3, and PPAR. (A and B) SRC-2 (A) and SRC-3 (B) were monitored along with lipids at the single 
cell level at the indicated time points. (C) Cell–cell variability, measured as the CV (/µ), of the indicated properties at 96 h. (D and E) SRC-2 (D) and SRC-3 
(E) normalized median intensities were monitored as a function of time in PPAR
lo and PPAR
hi cell populations by immunofluorescence. For each experiment 
and time point, individual cell measurements of PPAR and SRC were normalized to the median intensity at 96 h. PPAR normalization set the threshold 
for binary subdivision into PPAR
lo and PPAR
hi populations arbitrarily equal to 1. This threshold was then applied to each time point, and normalized SRC 
levels were calculated (*, P < 0.05 for PPAR
lo vs. PPAR
hi). (F) Shown are immunofluorescence images of SRC/PPAR/lipid (L) after 96 h of adipocyte 
differentiation from one representative experiment with (G) contour mapping of SRC/PPAR/lipid relationships. Density plots show normalized lipid expres-
sion as a function of normalized SRC and PPAR levels (n ≥ 1,900 cells). (H) Cells were divided into four quadrants based on their median PPAR and lipid 
levels, followed by calculation of the normalized median SRC-2 or SRC-3 intensity inside each population. In all experiments, SRC levels were normalized 
to the median intensity at 96 h (n = 6 independent experiments; *, P < 0.05). Error bars indicate SEM. Bars, 50 µm.JCB • VOLUME 192 • NUMBER 1 • 2011   60
SRC-2 and SRC-3 are essential for the 
adipocentric phenotype
The combination of qPCR, HCA, and FRET results led us to 
hypothesize that static, permissive SRC-2 and SRC-3 levels, 
occurring in the entire population contribute to an equilib-
rium condition that controls human adipogenesis. To perturb 
the postulated SRC-2 and SRC-3 equilibrium, we performed 
siRNA-based knockdowns (individually or in tandem) while   
simultaneously using antibodies to detect cell-to-cell changes in 
individual SRC protein levels. This approach uniquely allows 
cell-by-cell monitoring of target knockdown and any effect on 
differentiation. After a 48-h siRNA knockdown, preadipocytes 
were induced to differentiate for up to 96 h, and the extent of 
lipid accumulation and SRC levels was quantified by HCA. 
Shown in Fig. 6 A, single knockdown of SRC-2 or SRC-3 re-
sulted in decreased lipid accumulation. In line with previous 
observations (Louet et al., 2006), SRC-1 siRNA had no effect 
on lipogenesis or adipocentric gene expression (Fig. S2). More-
over, there was no apparent synergistic or additive inhibition 
of adipogenesis with dual SRC-2/SRC-3 siRNA knockdown. 
Additionally, siRNA targeting SRC-2 or SRC-3 did not alter 
the expression of the other CoR detected at the immunofluores-
cence level (Fig. S3 A) and quantified by HCA (Fig. 6 B). qPCR 
analyses of SRC levels in the median population levels for   
single or dual siRNA (Figs. 6 C and S3, B–F) showed consistent 
knockdown for both messages, validating our protein (HCA) 
measurements 6 d after transfection.
CFP  PPAR2/YFP  SRCs  were  cotransfected  for  48  h  and 
subsequently treated with MIX or vehicle (DMSO) for 2 h. 
A strong FRET signal, chiefly localized in a heterotypic pat-
tern  within  the  nucleus,  was  observed  when  CFP-PPAR/
YFP–SRC-2 or CFP-PPAR2/YFP–SRC-3 were coexpressed 
in HeLa cells (Fig. 5 A). FRET was measured both treatment 
conditions implying differentiation-independent interactions 
between SRCs and PPAR. Although vehicle treatment ex-
hibited a high basal level of FRET, statistically significant 
increases (>1.5-fold change) in FRET were detected in the 
presence of MIX (Fig. 5 B). Cells coexpressing YFP-SRC/
ECFP-NLS or CFP-PPAR2/EYFP-NLS were used as nega-
tive controls and exhibited significantly less FRET (Fig. 5 C) 
than PPAR–SRC fusion pairs.
Figure  5.    SRC-2  and  SRC-3  interact  with 
PPAR in a differentiation-independent manner.  
(A)  seFRET  was  used  to  evaluate  the  inter-
actions  between  CFP-PPAR2/YFP  SRC-2  or 
CFP-PPAR2/YFP  SRC-3  after  exposure  to   
either vehicle (DMSO) or MIX for 2 h in wild-
type  HeLa  cells.  Representative  images  are 
shown from one experiment for a single channel 
(CFP or YFP) with the calculated FRET image.   
Bars, 10 µm. (B) For each cell, the net FRET 
between  CFP-PPAR2  and  YFP-SRC  was  de-
termined  using  the  softWoRx  user  interface. 
FRET was measured within nucleoplasmic re-
gions  of  interest  only.  (C)  Control  plasmids, 
ECFP or EYFP fused to a NLS sequence, were 
coexpressed, and FRET was determined. On 
average,  CFP-PPAR2/YFP-SRC  FRET  signals 
were 8–20× greater than those measured in 
vector control experiments (n ≥ 22 cells mea-
sured  over  three  independent  experiments;   
*, P < 0.05 compared with vehicle treatment). 
FRET  signals  were  scaled  between  minimum 
and maximum signals (0–1,200 pixels), and 
intensity  was  colored  as  shown.  Error  bars   
indicate SEM.
Table I.  Pearson’s product moment correlation coefficients  









lo 0.21 ± 0.05 0.25 ± 0.10
PPAR
hi 0.16 ± 0.06 0.43 ± 0.10
PPAR/SRC-3
PPAR
lo 0.17 ± 0.10 0.13 ± 0.06
PPAR
hi 0.09 ± 0.08 0.33 ± 0.13
Data are presented as the mean ± SEM. n = 6.61 p160 coactivators promote adipocyte heterogeneity • Hartig et al.
down-regulation of SRC-2, SRC-3, or SRC-2/SRC-3 resulted in 
decreases in central adipogenic transcription factors (Fig. 6 H):   
PPAR (>29%) and C/EBP (>40%). Further, reductions in lipo-
genic gene expression were also measured (Fig. 6 H): ADFP 
(>57%), SREBP1c (>59%), and FASN (>64%). To probe the 
action of SRCs in gain-of-function experiments, SRC-1, SRC-2,   
and SRC-3 were overexpressed by lentiviral infection. Impor-
tantly, we ignored expression level artifacts that present them-
selves as protein aggregates (Stenoien et al., 2000, 2002; Feige 
et al., 2005). Although single or double SRC-2/SRC-3 siRNA 
decreased  lipogenesis,  moderate  (1.5–2.5  times  endogenous 
protein) overexpression of SRC-1, SRC-2, and SRC-3 showed 
modest increases in lipogenesis (<1.6-fold compared with 
FLAG control) after 96 h of differentiation (Fig. S5). Each of 
these results suggested that equilibrium levels of only SRC-2 
and SRC-3 are needed for human adipocyte differentiation and 
lipogenic gene regulation.
Quantification over a large span of experiments (n = 7 
independent replications, >1,000 cells/condition) showed that 
a >60% reduction in either or both SRC-2 and SRC-3 led to 
a 40% decrease (Fig. 6 D) in the number of lipid droplets/ 
nuclei without altering lipid droplet size (Fig. 6 E). We next 
determined the effect of SRC-2/SRC-3 on the rate of lipo-
genesis in the presence of a synthetic (BRL49653/rosiglitazone) 
or the natural PPAR agonist, 15dPGJ2 (Forman et al., 1995; 
Kliewer et al., 1995). In these loss-of-function experiments, 
SRC-2/SRC-3 single or joint knockdown slowed lipogenesis   
at 96 h by at least 50% (compared with scrambled siRNA con-
trol) without significantly affecting the induction of PPAR. 
Additionally, the effect was observed under differentiation with 
rosiglitazone (Fig. 6 F) or 15dPGJ2 (Fig. 6 G). This result sug-
gests that SRC-2 and SRC-3 are critical components of the basal 
adipogenic machinery, in agreement with in vivo data (Picard 
et al., 2002; Louet et al., 2006; Coste et al., 2008). By qPCR, 
Figure 6.  Single or double siRNA knockdown of SRC-2 and SRC-3 disrupts adipocyte differentiation without affecting PPAR protein induction. (A) Pre-
adipocytes were reverse-transfected with scrambled (scR) or siRNA to SRC-2, SRC-3, or both SRC-2/SRC-3 for 48 h followed by induction of differentia-
tion, and imaging. Bar, 50 µm. (B) HCA detection of p160 levels after siRNA transfection. (C) qPCR was used to validate measurements of SRC-2 or SRC-3 
knockdown by HCA. (D and E) Lipid droplet count (D) and lipid droplet area (E) were determined after siRNA knockdown and 4 d of differentiation (n = 7 
independent experiments). (F and G) The effects on the rate of lipogenesis and PPAR induction were determined by differentiation of preadipocytes for the 
indicated time points in the presence of either 3 µM BRL49653 (rosiglitazone; F) or 30 µM 15dPGJ2 (G) after SRC siRNA transfection (n = 3 independent 
experiments). (H) Heat map summary of the downstream effects of siRNA to SRC-2/SRC-3 on lipid accumulation markers as measured by qPCR: PPAR2, 
C/EBP, ADFP, FASN, and SREBP1c. RNA was isolated from two independent experiments. Asterisks indicate measured variables statistically different from 
the nontargeting siRNA control at the 95% confidence level (*, P < 0.05). Error bars indicate SEM.JCB • VOLUME 192 • NUMBER 1 • 2011   62
suggested: (a) up-regulation of phospho-PPAR levels coincided 
with (b) reduction of lipid accumulation and (c) enrichment of 
cells in a PPAR
hi/lipid
lo state. Simultaneous immunofluores-
cence detection of phospho-PPAR and total PPAR in our 
subpopulation analyses also showed that, with respect to the 
nontargeting  control,  the  mean  single  cell  intensity  ratio  of 
phospho-PPAR to PPAR (ph-PPAR/PPAR) was highest in 
the lipid
lo populations (Fig. 7 E). This finding was consistent 
with our hypothesis that the observed defect in lipogenesis was 
caused by a specific subpopulation up-regulation of phospho-
PPAR. Collectively, data from Figs. 6 and 7 suggest that per-
missive levels of the coactivators SRC-2 and SRC-3 attenuate 
phospho-PPAR to promote a full adipogenic response.
Discussion
The contribution of transcription factors and the associated regula-
tory machinery to the development of functional heterogeneity 
among white fat depots remains largely undiscovered, especially 
in the context of human adipogenesis. Recent cell culture studies 
(Le and Cheng, 2009; Loo et al., 2009) have indicated that concur-
rent physiological and molecular states may exist in differentiating 
3T3L1 preadipocytes largely as a response to systemic or growth 
factor stimulation. Additionally, PAR titrated knock-in transgenic 
mice (Tsai et al., 2009) demonstrated that selective reduction of 
PPAR only affected the accumulation of perigonadal fat, without 
decreasing retroperitoneal, inguinal, mesenteric, or subcapsular 
adipose mass, an indication that PPAR functional heterogeneity 
at the whole animal level can exist without compromising general-
ized adipogenesis. Our single cell–oriented data are consistent and 
expand upon these findings, showing a wide cell-to-cell variability 
(Fig. 3) in the early human adipocyte differentiation cascade.   
During this period, cells exhibit and support continuous PPAR 
states with and without lipids, even while robust activation of pro-
adipogenic genes occurs at the population level (Fig. 1).
Synthetic and natural ligands bind PPAR in a relatively 
large, promiscuous ligand-binding pocket that alters receptor   
conformation to assemble active transcriptional machinery 
(Nolte et al., 1998). Distinct from the hormonal up-regulation of   
PPAR and its effects upon its downstream targets, bulk mRNA 
(Fig. 1) and protein (Fig. 2) levels of pro-adipogenic coregulators 
SRC-2 and SRC-3 remain quite constant during the first 96 h of 
differentiation independent of natural (15dPGJ2) and synthetic 
(rosiglitazone) ligands (Fig. S2). Further examination of the 
cell–cell correlations between SRC-2, SRC-3, and PPAR re-
vealed that (a) PPAR
hi/lipid
hi cells also exhibited the highest 
SRC levels and a correlation between PPAR/SRC, whereas   
(b) all other PPAR/lipid populations showed little or no correla-
tion between PPAR and SRC (Table I). In addition to correlations 
between SRCs, PPAR, and lipids, we have also shown a ligand-
independent direct (FRET) interaction between SRC-2/PPAR 
and SRC-3/PPAR. Recent data suggests that the N-terminal 
A/B domain of PPAR can act as a docking site for coregula-
tors, in the absence of a ligand, to maintain a basal level of 
constitutive transcriptional activity, but it can also direct and 
enhance target gene specificity of the receptor (Gelman et al., 
1999; Feige et al., 2005; Molnár et al., 2005; Tudor et al., 2007).
SRC-2 and SRC-3 promote adipocyte 
heterogeneity and attenuate  
PPAR phosphorylation
Although our experiments revealed a central function of SRC-2 
and SRC-3 in promoting human adipogenesis both phenotypi-
cally (HCA) and transcriptionally (qPCR), follow-up experi-
ments showed that when PPAR mRNA was reduced by 29% 
(Fig. 6 H), PPAR protein levels and induction were not signifi-
cantly altered (Fig. 6, F and G). We then analyzed the cell–cell 
variability of PPAR and lipids after SRC siRNA knockdown 
(Fig. 7 A). For each experiment and transfection, individual cell 
measurements of PPAR and lipid were normalized to the me-
dian intensity of the scrambled control, which set the threshold 
for quadrant subdivision for both properties arbitrarily equal to 1.   
This threshold was then applied to each siRNA transfection to   
create the PPAR
x/lipid
y populations. As validation of the 
PPAR/lipid  gating,  PPAR  siRNA  inhibits  lipid  accumula-
tion (Fig. S4 C) and shifts the cells to a predominantly (73%) 
PPAR
lo/lipid
lo state by decreasing PPAR
hi fractions (Fig. S4 D). 
Although the total PPAR was largely unchanged at the whole 
population (Fig. 6 F) and subpopulation level (Fig. 7 B), siRNA 
to SRC-2 and/or SRC-3 caused shifts in each PPAR/lipid sub-
population. SRC siRNA increased the proportion of cells in   
a PPAR
lo/lipid
lo state by >4% while decreasing the PPAR
hi/
lipid
hi percentage >6%. Concurrent with these changes in sub-
population distributions, more significant effects were detected 
on the PPAR
lo/lipid
hi (13% to 15%) and the PPAR
hi/lipid
lo 
lipid populations (+15% to +19%). The changes in population 
variation indicate a role for SRC-2 and SRC-3 in controlling 
cell heterogeneity that promotes lipogenesis over a wide con-
tinuum of PPAR expression. Additionally, up-regulation of the 
PPAR
hi/lipid
lo population, along with decreases in downstream 
PPAR-dependent  (ADFP)  and  adipocentric/lipogenic  genes 
(Fig. 6 H), led us to hypothesize that the loss of the coactivators 
resulted in higher levels of PPAR phosphorylation at S114, 
leading to delayed/reduced adipogenesis.
MAPK–ERK phosphorylation of PPAR at S112/S114 
diminishes its ligand affinity, transcriptional activity, adipogenic 
capacity, and interactions with SRCs (Hu et al., 1996; Adams   
et al., 1997; Shao et al., 1998; Rangwala et al., 2003). We pos-
tulated  that  our  PPAR
hi/lipid
lo  populations  might  represent 
higher levels of phospho-PPAR S114 and that the presence   
of SRC-2 and/or SRC-3 minimizes this proportion of cells to 
promote adipocyte differentiation. To test this hypothesis, we 
knocked down SRC-2 and/or SRC-3 with siRNA and evaluated 
the levels of phospho-PPAR S114 at 0, 24, and 96 h after dif-
ferentiation. Upon immunolabeling with a specific antibody to 
phospho-PPAR S114 and total PPAR (Fig. 7 C), higher levels 
of phospho-PPAR were present when SRC-2 and/or SRC-3 
levels were reduced by siRNA. Further quantitative analysis in-
dicated increases in phospho-PPAR (Fig. 7 D) at each time 
point for individual knockdowns of SRC-2 (2.89-fold, 96 h) or 
SRC-3 (2.6-fold, 96 h), or when SRC-2 and SRC-3 (2.75-fold, 
96 h) are both knocked down, respectively. Contrasting the   
effect of SRC siRNA, scrambled siRNA (scR) reduces phospho- 
PPAR S114 by 32% over the 96-h differentiation period.   
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Figure 7.  SRC-2/SRC-3 single or double knockdown alters PPAR heterogeneity and phosphorylation status. (A) PPAR was immunolabeled and imaged 
by HTM with DAPI/CMBl and lipid counterstains under conditions of SRC-2, SRC-3, or SRC-2/SRC-3 siRNA. The effects of SRC-2/SRC-3 siRNA on sub-
population distributions (*, P < 0.05, n = 3) were tabulated. For each experiment and transfection, individual cell measurements of PPAR and lipid were 
normalized to the median intensity of the scrambled control, setting the threshold for quadrant subdivision for both properties arbitrarily equal to 1. This 
threshold was then applied to each siRNA transfection to create the PPAR
x/lipid
y populations. (B) The normalized median PPAR level was determined 
in each subpopulation for scrambled (scR) and SRC siRNA conditions. (C) Human preadipocytes were reverse-transfected with siRNA to SRC-2, SRC-3, or 
both coactivators and treated with MIX for up to 96 h. Subsequent to the perturbations, cells were immunolabeled with antibodies to phosphoPPAR-S114 
and total PPAR, followed by HTM imaging. Bar, 50 µm. (D) After imaging, phosphoPPAR-S114 was quantified for 0, 24, and 96 h of differentiation   
(*, P < 0.05; n = 3). (E) The single cell intensity ratios of phosphoPPAR-S114 to PPAR were determined for the lipid
lo and lipid
hi populations at 96 h   
(*, P < 0.05; n = 3). Error bars indicate SEM.JCB • VOLUME 192 • NUMBER 1 • 2011   64
implications for targeting the PPAR–SRC interaction surface 
as strategies for new therapeutics to prevent the onset of obesity 
associated with the treatment of type 2 diabetes.
Materials and methods
Primary cell culture and differentiation
Cryopreserved, subcutaneous primary human preadipocytes from normal 
female donors with a mean body mass index of 27.51 were provided by 
Zen-Bio Inc. Cells were maintained at 5% CO2/37°C in DME/F12 (Media-
tech, Inc.) with 10% FBS (Gemini Bio-Products), 100 U/ml penicillin, and 
100 µg/ml streptomycin (growth media). Medium was replaced during 
routine maintenance every 2 d. Cells were received at passage 2, and ex-
periments were performed before cells reached passage 10. Experiments 
were performed using pooled human preadipocytes from five individual 
female donors (Lot SL0033).
Unless otherwise indicated, all components were purchased from 
Sigma-Aldrich.  After  seeding  to  the  appropriate  experimental  format 
(coverslips, 96- or 384-well plate format), cells were differentiated using 
growth media supplemented with 100 nM human insulin, 0.250 mM IBMX,   
500 nM dexamethasone, and either rosiglitazone (BRL49653; Cayman 
Chemical Company) or 15dPGJ2 (Cayman Chemical Company). Unless 
otherwise indicated, differentiation was performed with IBMX, dexametha-
sone, human insulin, and 3 µM rosiglitazone.
Antibodies
The following antibodies were purchased from commercial sources and 
used for immunofluorescence: mouse monoclonal AIB1/SRC-3 (BD), mouse 
monoclonal  TIF2/SRC-2  (BD),  rabbit  polyclonal  phospho-PPAR  S112/
S114  (Abcam),  rabbit  monoclonal  PPAR  (Cell  Signaling  Technology), 
mouse  monoclonal  PPAR  (clone  E-8;  Santa  Cruz  Biotechnology,  Inc.), 
SRC-1 (BD), and mouse monoclonal FLAG-M2 (Sigma-Aldrich). Rabbit poly-
clonal antibody to SRC-3 was provided by B. O’Malley (Baylor College   
of Medicine, Houston, TX).
Immunofluorescence
For fluorescence detection of antibodies and neutral lipid content in multi-
well plates, the following protocol was performed on the BioMek NX (Beck-
man Coulter). The well plate systems used were: 96-well and 384-well 
(Sensoplate Plus; Greiner). Aspirations and plate washes were performed 
with an ELx405 (BioTek). After differentiation, media was aspirated, and 
4% paraformaldehyde (ultrapure; Electron Microscopy Sciences) in PBS 
was immediately added for 30 min at room temperature. Plates were then 
quenched with 100 mM ammonium chloride. After quenching, plates were 
washed three times with TBS. Fixed adipocytes were permeabilized with 
0.1% Triton X-100 in TBS for 10 min and washed three times with TBS.   
A 2% BSA in TBS/0.01% saponin (antibody diluent) blocking solution 
was added for 30 min at room temperature followed by three TBS washes. 
Antibodies were then diluted at a 1:200 concentration in antibody dilu-
ent and incubated overnight at 4°C. Subsequently, plates were washed 
with TBS and incubated with secondary antibodies for 1 h at room tem-
perature. Alexa Fluor 647–-conjugated anti–mouse and Alexa Fluor 568– 
conjugated  anti–rabbit  secondary  antibodies  (Invitrogen)  were  used. 
Cells were again washed three times and incubated with 1 µg/ml Cell-
Mask blue (CMBl; Invitrogen), 1:1,000 LipidTOX green (Invitrogen), and   
10 µg/ml DAPI in PBS for 45 min at room temperature. Dyes were then 
aspirated and PBS/0.01% azide was added. Plates were then sealed and 
imaged immediately.
seFRET imaging
CFP/YFP FRET experiments were performed using PPAR2-ECFP (provided 
by F. Schaufele, University of California, San Francisco, CA), EYFP-SRC-2 
(R.  Michalides,  Netherlands  Cancer  Institute,  Amsterdam,  Netherlands) 
and EYFP-SRC-3 (Amazit et al., 2007) expressed in HeLa cells grown on 
standard 12-mm glass coverslips. Constructs were cotransfected using Lipo-
fectamine 2000 (Invitrogen). Media was removed and replaced with fresh 
DME/F12 with 5% FBS 24 h after transfection. After a further 24 h, cells 
were treated for 2 h with either DMSO or differentiation cocktail (IBMX, 
human  insulin,  dexamethasone,  and  rosiglitazone),  both  prepared  in 
growth media (DME/F12, 5% FBS). Treatment was followed with these 
steps: fixation 4% PFA (30 min), quench 100 mM NH4Cl (10 min), and 
mount with SlowFade Gold (Invitrogen). After fixation, cells were washed 
with PBS++ three times, while all other wash steps were performed with 
Pipes/Hepes/EGTA/MgCl2 (PEM) buffer, prepared at a final pH of 6.8.
In contrast to the SRC-1/SRC-3 double knockout mouse 
(Wang et al., 2006), the SRC-2/SRC-3 and SRC-1/SRC-2   
mutant mice are lethal (Mark et al., 2004; Xu et al., 2009), mak-
ing our experiments the first to analyze compensation between 
SRC-2 and SRC-3 during human adipogenesis. Although over-
expression suggested that SRC-1, SRC-2, and SRC-3 modestly 
increase adipogenesis, siRNA established that the endogenous 
levels of SRC-2 and SRC-3 are essential for differentiation.   
To determine if a functional overlap exists specifically between 
SRC-2  and  SRC-3  during  differentiation  of  cultured  human   
adipocytes, we used a dual siRNA approach. Strikingly, we found 
that single or double knockdown of SRC-2 and SRC-3 inhibited 
adipogenesis to the same extent for both natural (15dPGJ2) and 
synthetic PPAR ligands with comparable PPAR induction. 
Consistent with pro-adipogenic SRCs being dominant in adipo-
cyte development (Wang et al., 2006), SRC-1 siRNA had no   
effect on differentiation. This result suggests that SRC-2 and 
SRC-3 are fundamental components of the basal, preligand   
adipogenic machinery driven by PPAR. The data at both the 
phenotypic (Fig. 6, A–G) and gene regulatory level (Fig. 6 H) did 
not exhibit any apparent compensation by the nontargeted SRCs 
in single siRNA treatments. In support of this finding, it has 
been proposed that SRC-2 and SRC-3 preferentially pair and 
interact to promote gene transcription (Zhang et al., 2004).
Upon single or double SRC-2/SRC-3 siRNA treatment, 
PPAR protein levels were unchanged; interestingly, there was 
an enrichment of cells in a PPAR
hi/lipid





hi proportions (Fig. 7 A). 
Coincident with decreased expression of PPAR downstream 
genes, the increased PPAR
hi/lipid
lo population reflected an in-
crease in the amount of phospho-PPAR S114 (Fig. 7 D). When 
the levels of coactivator are reduced, the signal transduction 
environment elevates phospho-PPAR S112/S114 status, low-
ers ligand (thiazolidinedione/eicosanoid) affinity, and increases 
interactions with the corepressors SMRT (Shao et al., 1998) or 
PER2 (Grimaldi et al., 2010) to reduce transcriptional activity 
(Lavinsky et al., 1998). Collectively, these results imply that 
SRC-2 and SRC-3, together, collaborate to promote adipocyte 
differentiation through potential multimerization (McKenna   
et al., 1998) and/or dimerization via protein dimerization/ 
interaction domains (Lodrini et al., 2008). To add to this model, 
we combined quantitative analysis of SRC/PPAR/lipid kinet-
ics, correlations, FRET data, and loss-of-function experiments 
at single cell resolution. These important single cell char-
acteristics suggest a novel mechanism of action. Specifically, 
permissive, homeostatic levels of SRC-2 and SRC-3 can inter-
act with the PPAR in the absence of MIX to regulate PPAR 
heterogeneity, reduce inhibitory PPAR phosphorylation, and 
promote adipogenesis.
Our  quantitative,  cell-by-cell  approach  has  identified  a 
unique interplay between SRC-2, SRC-3, and PPAR that pro-
motes adipogenesis. Small molecule inhibitors that block SRC 
recruitment or disrupt the predifferentiation complex between 
SRCs and PPAR might maintain the positive (insulin sensiti-
zation) while reducing negative (weight gain) effects of thia-
zolidinediones  (Reginato  et  al.,  1998;  Rocchi  et  al.,  2001; 
Michalik et al., 2006). Collectively, the data presented here have 65 p160 coactivators promote adipocyte heterogeneity • Hartig et al.
TE2000-U) and a triple band filter set (Chroma 82000; Chroma Technol-
ogy Corp.). A progressive scan camera (COHU) functioned as the focusing 
camera. The imaging camera (Hamamatsu Photonics) was set to capture 
8-bit images at 2 × 2 binning (672 × 512 pixels, 0.684 × 0.684 µm
2/pixel) 
with five images captured per field (DAPI, CMBl, LipidTOX, Alexa Fluor 
568, and Alexa Fluor 647 secondary antibodies). All high-throughput 
microscopy experiments were performed with an S Fluor 20×/0.75 NA 
objective lens (Nikon). In general, 12–16 images were captured per well 
for image analysis. All imaging was performed at room temperature.
Image analysis
Images were analyzed using custom algorithms developed with the Pipeline 
Pilot (v7.5) software platform (Accelrys) in a similar workflow as described 
previously (Szafran et al., 2008, 2009) and summarized in the following 
steps. After background subtraction, nuclear and cell masks were gener-
ated using a combination of nonlinear least squares and watershed-from-
markers image manipulations of the DAPI images. Specifically, a nonlinear 
least squares threshold was applied to a DAPI image to create a binary 
image. This image was subsequently eroded and distance transformed 
to generate a marker image identifying the approximate center for each   
nuclei. This marker image in combination with the original DAPI image was 
used in a watershed-from-markers operation to define the full nuclear mask 
for each nucleus. A final morphological open operation was used to gener-
ate the final nuclear masks. Then, cellular masks were created by applying 
watershed segmentation on the CellMask images using nuclei regions as 
seeds. To prevent cell body oversegmentation, cell regions were trimmed 
so their boundaries did not exceed an empirically determined maximal 
distance from the nucleus. All events with whole cell masks bordering the 
edge of the image were additionally eliminated from analysis. Both whole 
cell and nucleus segmentation generate regions under which single cell 
intensity features were extracted. Cell populations were filtered to discard 
events with cell aggregates, mitotic cells, apoptotic cells, cellular debris, or 
poor segmentation. Applied gates were based upon nuclear area, nuclear 
circularity, and cell size/nucleus ratio. In general, these filters removed 
10% of the population of segmented cells. An additional image analysis 
platform, CyteSeer (Vala Sciences), was also used to support the Pipe-
line  Pilot-driven  algorithms.  Measurements  extracted  using  lipid  droplet 
analysis intrinsic to CyteSeer software (McDonough et al., 2009) included 
lipid droplet count, total integrated intensity of the lipid mask on the lipid   
image, and lipid droplet area. Post-analysis measurements were exported 
to spreadsheet software (Excel; Microsoft) for further analysis.
Statistical analyses
Data presented were acquired from a minimum of two (qPCR) or three 
(HCA) independent experiments performed on multiple days, unless other-
wise indicated. Analysis of variance (ANOVA) was first used to compare 
the effects of time or siRNA treatment. If significant differences were identi-
fied, then data were compared with Tukey’s HSD post-hoc tests. All tests 
were performed at the 95% confidence interval using JMP-IN 7 (SAS).
Online supplemental material
Fig. S1 shows the extension of the human adipogenesis assay to later 
time points and dose response experiments for BRL49653 and 15dPGJ2 
with detection of SRC-1, SRC-2, SRC-3, PPAR, and lipid content. Fig. S2   
shows the effect of SRC-1 siRNA on human adipogenesis. Fig. S3 dis-
plays  immunofluorescent  detection  of  SRC-2  and  SRC-3  under  single 
or  double  knockdown  conditions.  Fig.  S3  also  redisplays  mRNA  data 
represented in Fig. 6 H. Fig. S4 shows the validation of subpopulation 
analyses using PPAR siRNA. Fig. S5 describes SRC gain-of-function ex-
periments. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201004026/DC1.
The authors thank Drs. N. McKenna and Z.D. Sharp for critically reviewing the 
manuscript; I.P. Uray for qPCR assay design; J.Y. Newberg, A.T. Szafran,   
M.G. Mancini, L. Vergara, and J. Broughman for technical resource support; 
and P. McDonough and J.H. Price (Vala Sciences) for longstanding support in 
automated cytometry. Benjamin Buehrer is an employee of Zen-Bio, Inc.
This  work  was  funded  by  National  Institutes  of  Health  (NIH)  grant 
5R01DK055622, the Hankamer Foundation, and pilot grant and equipment sup-
port from the John S. Dunn Gulf Coast Consortium for Chemical Genomics (to   
M.A. Mancini). Additional funding was provided by NIH 1F32DK85979 (to 
S.M. Hartig), 5T32HD007165 (to B.W. O’Malley), 5K01DK081446 (to B. He), 
and 5R01CA090464 (to E. Chang). Imaging resources were supported by   
Specialized Cooperative Centers Program in Reproduction U54 HD-007495   
(to B.W. O’Malley), P30 DK-56338 (to M.K. Estes), P30 CA-125123 (to C.K. 
Osborne), and the Dan L. Duncan Cancer Center of Baylor College of Medicine.
FRET  imaging  was  performed  as  described  previously  (Trinkle- 
Mulcahy et al., 2001; Chusainow et al., 2006) with the DeltaVision Core 
Image Restoration Microscope (Applied Precision). Z stacks were imaged at 
0.2 µm separation and a frame size of 1,024 × 1,024 pixels at 1 × 1 bin-
ning with a microscope (IX71; Olympus) using a 60×, 1.42 NA Plan Achro-
mat objective (Olympus) and a charge-coupled device camera (CoolSnap 
HQ2; Photometrics). Filter sets were as follows, with a dichroic to split CFP 
and YFP: excitation 430 nm/emission 470 nm (CFP), excitation 500 nm/
emission 535 nm (YFP), and excitation 430 nm/emission 535 nm (FRET).   
Z series stacks were deconvolved with the DeltaVision constrained iterative 
algorithm. After deconvolution (softWoRx; Applied Precision), FRET calcula-
tions were performed using the Applied Precision FRET user interface. FRET 
measurements on individual nuclei were acquired on maximum intensity pro-
jections of the derived FRET image. Spectral bleed-through was corrected for 
by acquiring specimens containing only CFP-PPAR2 and YFP-p160. Stan-
dard values for  and  coefficients were 0.6 (CFP) and 0.12 (YFP) acquired 
from single donor/acceptor plasmid expression experiments.
siRNA transfection
siRNA to SRC-2 and SRC-3 oligomers was provided by E. Lader (QIAGEN, 
Germantown, MD). Before transfection, optical quality 384-well plates (Senso-
Plate Plus; Greiner) were coated with 20 µl of FBS (Gemini Bio-Products) 
overnight at 37°C. Cells were reverse-transfected with siRNA or mismatch 
control at a final concentration of 10 nM using HiPerFect transfection reagent   
(QIAGEN). siRNA and transfection reagents were mixed in OptiMEM I reduced 
serum media (Invitrogen) and allowed to complex at room temperature for   
20 min. Preadipocytes, diluted to a final density of 5,000 cells/well, were 
then added to the HiPerFect–siRNA complexes followed by immediate seed-
ing to plates. The total volume of cells and transfection reagent was 30 µl/
well. Final volume of each condition upon seeding to the 20 µl FBS coat was 
50 µl/well. After reverse transfection, cells were incubated for 48 h at 5% 
CO2/37°C before induction of differentiation for up to 96 h.
Production of lentiviral particles
SRC-1, SRC-2, and SRC-3 cDNAs were cloned into the lentiviral expres-
sion vector pCDH–CMV-MCS-EF1-Puro (System Biosciences) by XbaI–NheI 
digestion. Pseudolentiviruses were produced in 293TN cells by cotrans-
fecting lentiviral expression constructs and the pPACK packaging plasmid 
mix (System Biosciences). Pseudoviral particles were harvested 48 h after 
transfection and were concentrated using a PEG-it virus precipitation solu-
tion kit (System Biosciences).
RNA extraction and qPCR analysis
Total RNA was extracted from cells using TRIzol reagent (Invitrogen) ac-
cording to the manufacturer’s instructions. To measure the relative mRNA 
levels of SRC-2, SRC-3, PPAR, and adipocentric genes (ADFP, SREBP1c, 
FASN, and C/EBP), quantitative real-time RT-PCR was performed using 
the Taqman RT-PCR one-step master mix in conjunction with an ABI 7500 
real-time PCR system (Applied Biosystems). Each sample was tested in du-
plicate in three independent experiments. -actin was used as the invariant 
control. For C/EBP, relative mRNA was evaluated using the TaqMan 
Gene Expression Assay (Assay ID Hs00269972_s1). The following primer 
and  probe  sets  were  used  to  detect  SREBP1c,  FASN,  SRC-2,  SRC-3, 
PPAR2, and ADFP. SREBP1c: 5-TGCGCAAGACAGCAGATTTA-3 (for-
ward), 5-CGCTCCTCCATCAATGACA-3 (reverse), and Roche Universal 
ProbeLibrary probe No. 77 (probe); FASN: 5-CGGAGTGAATCTGGG-
TTGAT-3 (forward), 5-CAGGCACACACGATGGAC-3 (reverse), and 
Roche Universal Probe Library probe No. 11 (probe); SRC-2: 5-GGAC-
CTGGTAAGAAGGTGTATTCAG-3  (forward),  5-TGCCTCTTAGCATAG-
GACACAGA-3  (reverse),  and  5-TCCATGCGCAGCATGAAGGAGA-3 
(probe); SRC-3: 5-TTCAGGAAAGGTTGTCAATATAGATACA-3 (forward), 
5-AATACACCTTCGGATTATATCTTCAAA-3  (reverse),  and  5-TTCACTGA-
GATCCTCCATGAGGCCTG-3  (probe);  ADFP:  5-GTGACTGGCAGTGT-
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